Blood sugar & insulin stories

Apr 25, 2026

Continuous Glucose Monitors Significantly Improve Blood Sugar Control in Type 2 Diabetes Patients on Insulin

A major clinical trial found that real-time continuous glucose monitoring (CGM) significantly improves blood glucose management in adults with type 2 diabetes treated with basal insulin, offering evidence for expanded use of the technology beyond type 1 diabetes.

Apr 25, 2026·1 source

Apr 13, 2026

Genetic Variants Explain Why GLP-1 Drugs Like Ozempic Don't Work for 10% of Patients

New research reveals that approximately 10% of people carry specific genetic variants that make popular diabetes and weight-loss drugs like Ozempic and Wegovy significantly less effective, providing the first genetic explanation for variable drug response.

Apr 13, 2026·1 source

Apr 9, 2026

Study Links $35 Insulin Cap to Improved Treatment Adherence in Type 2 Diabetes

Research demonstrates that capping insulin costs at $35 per month significantly improves medication adherence among patients with type 2 diabetes, providing evidence for price control policies.

Apr 9, 2026·1 source

Top claims

▪Type 2 diabetes patients on basal insulin may gain access to monitoring technology previously reserved primarily for type 1 diabetes patients.
▪Continuous glucose monitoring technology offers type 2 diabetes patients on basal insulin better tools for managing their blood glucose levels.
▪Physicians treating type 2 diabetes can now consider continuous glucose monitoring as a clinically validated intervention for patients using basal insulin.

Subtopics

Glucose monitoring Clinical trials Wearables & health tracking Supplementation fundamentals Metabolic health

GLP-1 medications

Biomarkers & bloodwork testing

Nutrition fundamentals

Related timelines

Blood sugar & insulin stories

Continuous Glucose Monitors Significantly Improve Blood Sugar Control in Type 2 Diabetes Patients on Insulin

Genetic Variants Explain Why GLP-1 Drugs Like Ozempic Don't Work for 10% of Patients

Study Links $35 Insulin Cap to Improved Treatment Adherence in Type 2 Diabetes

Related timelines

US Congress

Venture capital funding

Iran War

Strait of Hormuz blockage

Trump administration